\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ revealed\\ bilateral\\ nasal\\ polyps\\.\ \(0\)\
\-\ patient\\ underwent\\ bifrontal\\ craniotomy\\ and\\ lateral\\ rhinotomy\\.\ \(0\)\
\-\ mri\\ of\\ the\\ brain\\ pre\\ and\\ post\\ gadolinium\\ demonstrates\\ a\\ t1\\ dark\\,\\ t2\\ intermediate\\ to\\ hyperintense\\ lesion\\ emanating\\ from\\ the\\ anterior\\ cranial\\ fossa\\ into\\ the\\ left\\ nasal\\ region\\ with\\ moderate\\,\\ homogeneous\\ contrast\\ enhancement\\.\\ \\ there\\ is\\ also\\ a\\ t1\\ dark\\,\\ t2\\ bright\\ signal\\ present\\ in\\ the\\ left\\ maxillary\\ sinus\\,\\ sphenoid\\ sinus\\,\\ and\\ the\\ left\\ frontal\\ ethmoid\\ recess\\,\\ which\\ demonstrates\\ a\\ peripheral\\ rim\\ of\\ enhancement\\.\ \(0\)\
\-\ olfactory\\ neuroblastoma\ \(0\)\
\-\ neoplastic\ \(113\)\
\-\ olfactory\\ neuroblastoma\ \(0\)\
\-\ squamous\\ cell\\ carcinoma\ \(52\)\
\-\ extramedullary\\ plasmacytoma\ \(0\)\
\-\ meningioma\ \(167\)\
\-\ lymphoma\ \(373\)\
\-\ melanoma\ \(92\)\
\-\ rhabdomyosarcoma\ \(41\)\
\-\ non\\-neoplastic\ \(2\)\
\-\ frontoethmoid\\ mucocele\ \(0\)\
\-\ invasive\\ aspergilloma\ \(0\)\
\-\ nasal\\ polyposis\ \(2\)\
\-\ 50\\ year\\-old\\,\\ white\\ male\\ with\\ 12\\ month\\ history\\ of\\ left\\ nasal\\ obstruction\\ and\\ recurrent\\ epistaxis\\.\ \(1\)\
\-\ ct\\ and\\ mri\\ are\\ valuable\\ tools\\ in\\ evaluating\\ anterior\\ skull\\ base\\ tumors\\.\\ \\ while\\ the\\ appearances\\ of\\ these\\ tumors\\ tend\\ to\\ be\\ nonspecific\\,\\ there\\ are\\ certain\\ characteristics\\ that\\ may\\ help\\ in\\ narrowing\\ the\\ differential\\ such\\ as\\.\\.\\.\ \(0\)\
\-\ broad\\-based\\ interface\\ with\\ the\\ anterior\\ cranial\\ fossa\ \(0\)\
\-\ \\ \\ \\ \\-squamous\\ cell\\ carcinoma\\,\\ esthesioneuroblastoma\\,meningioma\ \(1\)\
\-\ marginal\\ cysts\ \(0\)\
\-\ \\ \\ \\ \\-esthesioneuroblastoma\ \(1\)\
\-\ diffuse\\,\\ marked\\ enhancement\ \(0\)\
\-\ \\ \\ \\ \\-meningioma\\,\\ hemangiopericytoma\\,\\ plasmacytoma\ \(1\)\
\-\ tumoral\\ calcifications\ \(1\)\
\-\ \\ \\ \\ \\-chondrosarcoma\\,\\ teratoma\\,\\ meningioma\\,\\ esthesioneuroblastoma\ \(1\)\
\-\ linear\\ \\"dural\\ tail\\"\\ of\\ enhancement\ \(0\)\
\-\ \\ \\ \\ \\-meningiomas\\,\\ neuromas\\,\\ mets\\,\\ adenocystic\\ carcinomas\ \(1\)\
\-\ sclerotic\\ or\\ hyperostotic\\ bone\\ reaction\ \(0\)\
\-\ \\ \\ \\ \\-osteoblastic\\ mets\\,\\ meningiomas\\,\\ fibro\\-osseous\\ lesions\\,\ \(1\)\
\-\ \\ \\ \\ \\ pervious\\ radiotherapy\ \(1\)\
\-\ bone\\ destruction\ \(12\)\
\-\ \\ \\ \\ \\-scc\\,\\ sarcomas\\,\\ mets\\,\\ lymphoma\ \(0\)\
\-\ bony\\ remodeling\ \(8\)\
\-\ \\ \\ \\ \\-neuromas\\,\\ meningiomas\\,\\ plasmacytomas\\,\\ sarcomas\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ esthesioneuroblastoma\\:\\ 0\\.3002472132137037\ \(0\)\
\-\ nasal\\:\\ 0\\.23883442581038244\ \(0\)\
\-\ meningiomas\\:\\ 0\\.23008955620234758\ \(0\)\
\-\ mets\\:\\ 0\\.20199216231402314\ \(0\)\
\-\ meningioma\\:\\ 0\\.19630142537508372\ \(0\)\
\-\ neuromas\\:\\ 0\\.18843500800424323\ \(0\)\
\-\ olfactory\\:\\ 0\\.16479243780710467\ \(0\)\
\-\ sarcomas\\:\\ 0\\.16479243780710467\ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.15548197112303377\ \(0\)\
\-\ enhancement\\:\\ 0\\.15078662773861556\ \(0\)\
\-\ dark\\:\\ 0\\.12850144686057616\ \(0\)\
\-\ neoplastic\\:\\ 0\\.12106650675418548\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.12034511435192465\ \(0\)\
\-\ anterior\\:\\ 0\\.10970246862664204\ \(0\)\
\-\ cranial\\:\\ 0\\.10705949385945059\ \(0\)\
\-\ pervious\\:\\ 0\\.10473763774660332\ \(0\)\
\-\ plasmacytomas\\:\\ 0\\.10473763774660332\ \(0\)\
\-\ the\\:\\ 0\\.10454588568313328\ \(0\)\
\-\ fossa\\:\\ 0\\.10282874569434065\ \(0\)\
\-\ hyperostotic\\:\\ 0\\.10008240440456788\ \(0\)\
\-\ rhinotomy\\:\\ 0\\.09677946378451796\ \(0\)\
\-\ adenocystic\\:\\ 0\\.09677946378451796\ \(0\)\
\-\ tumors\\:\\ 0\\.09633352701164868\ \(0\)\
\-\ sinus\\:\\ 0\\.09464966233054427\ \(0\)\
\-\ tools\\:\\ 0\\.09421750400212162\ \(0\)\
\-\ aspergilloma\\:\\ 0\\.09212423044248252\ \(0\)\
\-\ left\\:\\ 0\\.08936442499226985\ \(0\)\
\-\ emanating\\:\\ 0\\.08625933004003626\ \(0\)\
\-\ polyposis\\:\\ 0\\.08516505307763454\ \(0\)\
\-\ valuable\\:\\ 0\\.08416605648039717\ \(0\)\
\-\ bifrontal\\:\\ 0\\.08324706869551177\ \(0\)\
\-\ appearances\\:\\ 0\\.08239621890355234\ \(0\)\
\-\ tumoral\\:\\ 0\\.08239621890355234\ \(0\)\
\-\ t1\\:\\ 0\\.08161251997870078\ \(0\)\
\-\ epistaxis\\:\\ 0\\.08160409669800081\ \(0\)\
\-\ carcinoma\\:\\ 0\\.07834995932197177\ \(0\)\
\-\ lymphoma\\:\\ 0\\.07801032794397884\ \(0\)\
\-\ recess\\:\\ 0\\.07720687911554919\ \(0\)\
\-\ t2\\:\\ 0\\.07535991395619106\ \(0\)\
\-\ marginal\\:\\ 0\\.0752888947334264\ \(0\)\
\-\ cell\\:\\ 0\\.07493007898511841\ \(0\)\
\-\ certain\\:\\ 0\\.07403515384495893\ \(0\)\
\-\ mucocele\\:\\ 0\\.07326945562830851\ \(0\)\
\-\ carcinomas\\:\\ 0\\.07326945562830851\ \(0\)\
\-\ remodeling\\:\\ 0\\.0729049418982619\ \(0\)\
\-\ interface\\:\\ 0\\.07155264917627638\ \(0\)\
\-\ bone\\:\\ 0\\.07147009390135255\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.07093189161629058\ \(0\)\
\-\ polyps\\:\\ 0\\.07063366139139096\ \(0\)\
\-\ craniotomy\\:\\ 0\\.07005948084501884\ \(0\)\
\-\ hemangiopericytoma\\:\\ 0\\.06951265282643695\ \(0\)\
\-\ ethmoid\\:\\ 0\\.0684914273391781\ \(0\)\
\-\ and\\:\\ 0\\.06766668019482185\ \(0\)\
\-\ mri\\:\\ 0\\.06723663678369783\ \(0\)\
\-\ intermediate\\:\\ 0\\.06689741583424093\ \(0\)\
\-\ tend\\:\\ 0\\.06689741583424093\ \(0\)\
\-\ sphenoid\\:\\ 0\\.06588071496501487\ \(0\)\
\-\ evaluating\\:\\ 0\\.06588071496501487\ \(0\)\
\-\ demonstrates\\:\\ 0\\.06580598783637889\ \(0\)\
\-\ maxillary\\:\\ 0\\.06494676793617654\ \(0\)\
\-\ tail\\:\\ 0\\.06459347181142838\ \(0\)\
\-\ of\\:\\ 0\\.06408349566177973\ \(0\)\
\-\ nonspecific\\:\\ 0\\.0615544788643516\ \(0\)\
\-\ help\\:\\ 0\\.06017255717596232\ \(0\)\
\-\ characteristics\\:\\ 0\\.06005480006050134\ \(0\)\
\-\ bright\\:\\ 0\\.05970860645259561\ \(0\)\
\-\ destruction\\:\\ 0\\.05970860645259561\ \(0\)\
\-\ dural\\:\\ 0\\.058118805920788205\ \(0\)\
\-\ homogeneous\\:\\ 0\\.0578256525114078\ \(0\)\
\-\ teratoma\\:\\ 0\\.05663529784934303\ \(0\)\
\-\ reaction\\:\\ 0\\.05571631006445762\ \(0\)\
\-\ sclerotic\\:\\ 0\\.05494025674621719\ \(0\)\
\-\ gadolinium\\:\\ 0\\.05457105393376536\ \(0\)\
\-\ pre\\:\\ 0\\.05352974692972529\ \(0\)\
\-\ skull\\:\\ 0\\.05313830385302068\ \(0\)\
\-\ linear\\:\\ 0\\.05275976787107538\ \(0\)\
\-\ recurrent\\:\\ 0\\.05251417095327529\ \(0\)\
\-\ rim\\:\\ 0\\.052155353684823894\ \(0\)\
\-\ there\\:\\ 0\\.05211895915444348\ \(0\)\
\-\ hyperintense\\:\\ 0\\.052096626098415984\ \(0\)\
\-\ narrowing\\:\\ 0\\.05077039744689676\ \(0\)\
\-\ bony\\:\\ 0\\.05046146711114845\ \(0\)\
\-\ base\\:\\ 0\\.04981933919951184\ \(0\)\
\-\ are\\:\\ 0\\.04970326437687681\ \(0\)\
\-\ cysts\\:\\ 0\\.049628775188084694\ \(0\)\
\-\ marked\\:\\ 0\\.04953466631601963\ \(0\)\
\-\ moderate\\:\\ 0\\.049165760103061715\ \(0\)\
\-\ in\\:\\ 0\\.04887763265826167\ \(0\)\
\-\ calcifications\\:\\ 0\\.04779835056768808\ \(0\)\
\-\ peripheral\\:\\ 0\\.046832973959656084\ \(0\)\
\-\ obstruction\\:\\ 0\\.0458741701691658\ \(0\)\
\-\ 50\\:\\ 0\\.045738696997254365\ \(0\)\
\-\ underwent\\:\\ 0\\.04511616750762395\ \(0\)\
\-\ 12\\:\\ 0\\.04477060544723672\ \(0\)\
\-\ white\\:\\ 0\\.043210455941324666\ \(0\)\
\-\ revealed\\:\\ 0\\.042943438834271055\ \(0\)\
\-\ differential\\:\\ 0\\.04255420772522759\ \(0\)\
\-\ while\\:\\ 0\\.0423268494420964\ \(0\)\
\-\ frontal\\:\\ 0\\.0421530763372232\ \(0\)\
\-\ such\\:\\ 0\\.04212846492777819\ \(0\)\
\-\ diffuse\\:\\ 0\\.04107224604992047\ \(0\)\
\-\ brain\\:\\ 0\\.04082819164474834\ \(0\)\
\-\ month\\:\\ 0\\.039840176605602726\ \(0\)\
\-\ region\\:\\ 0\\.03917497966098588\ \(0\)\
\-\ with\\:\\ 0\\.038473071321100435\ \(0\)\
\-\ lesions\\:\\ 0\\.037613399005554576\ \(0\)\
\-\ signal\\:\\ 0\\.037126145485977854\ \(0\)\
\-\ these\\:\\ 0\\.03698391247220707\ \(0\)\
\-\ post\\:\\ 0\\.03563685633781957\ \(0\)\
\-\ physical\\:\\ 0\\.035511832763641185\ \(0\)\
\-\ bilateral\\:\\ 0\\.03519837944779194\ \(0\)\
\-\ into\\:\\ 0\\.0348149755719899\ \(0\)\
\-\ present\\:\\ 0\\.03360660883641308\ \(0\)\
\-\ exam\\:\\ 0\\.0329692318986984\ \(0\)\
\-\ may\\:\\ 0\\.03295816566351914\ \(0\)\
\-\ to\\:\\ 0\\.032746265489761874\ \(0\)\
\-\ lateral\\:\\ 0\\.032502760203503143\ \(0\)\
\-\ contrast\\:\\ 0\\.03182173364365347\ \(0\)\
\-\ lesion\\:\\ 0\\.031398822981289085\ \(0\)\
\-\ also\\:\\ 0\\.03080605165166193\ \(0\)\
\-\ which\\:\\ 0\\.029780339446596204\ \(0\)\
\-\ male\\:\\ 0\\.02916002329366185\ \(0\)\
\-\ that\\:\\ 0\\.028421525686927365\ \(0\)\
\-\ be\\:\\ 0\\.026567910318996565\ \(0\)\
\-\ as\\:\\ 0\\.026310880779163492\ \(0\)\
\-\ from\\:\\ 0\\.026011061084336276\ \(0\)\
\-\ history\\:\\ 0\\.025022134848335383\ \(0\)\
\-\ ct\\:\\ 0\\.024933817350461254\ \(0\)\
\-\ or\\:\\ 0\\.022783864360255972\ \(0\)\
\-\ patient\\:\\ 0\\.02130159989917176\ \(0\)\
\-\ is\\:\\ 0\\.01793571549001097\ \(0\)\
